DOR BioPharma Initiates New Botulinum Toxin Therapeutic Program
Capitalizing on research focused on structure/function relationships of Botulinum toxin done by Lance Simpson, Ph.D., Director, Center for Research on Bioterrorism and Biodefense, Thomas Jefferson University Philadelphia, the inventor of DOR's oral Botulinum toxin vaccine, BT-VACC(TM), DOR has entered into an agreement with Blue Dolphin, LLC, a firm specializing in rational drug design, to apply computer-aided design to the discovery of new drug leads against Botulinum toxin.
Under the agreement, Blue Dolphin will propose novel drug-like inhibitors of Botulinum toxin by targeting a new site on the toxin's structure identified by Dr. Simpson. Millions of candidate molecules will be modeled for structural and chemical fit to the target site on the toxin using computer aided discovery techniques. The best fitting molecules will be experimentally tested by Dr. Simpson for their effectiveness in treating Botulinum toxin exposure. By focusing on the structure of the Botulinum toxin, as opposed to derivatives of previously known inhibitors, this "virtual screening" will allow DOR to target new parts of the toxin with new candidate inhibitors.
Most read news
Organizations
Other news from the department science
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.